An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram
The DOI matches its Crossref record.
Abstract
The selective serotonin reuptake inhibitors (SSRIs) have recently been associated with a variety of somatic and psychiatric symptoms upon abrupt drug discontinuation. These symptoms have been variously termed SSRI withdrawal, or SSRI discontinuation syndrome. Although all of the available SSRIs have been reported to cause discontinuation symptoms, some appear to have a greater propensity to cause these adverse events than others. Data from a previously completed placebo-controlled, double-blind study designed to assess citalopram in depression relapse prevention were analysed to assess patients for the emergence of discontinuation effects following randomization to placebo after 8 weeks of active drug treatment. Side-effects that occurred during the first 2 weeks following randomization to active drug (n = 150) or placebo (n = 72) were measured using the UKU unwanted side-effect list. The proportion of patients that experienced one or more events over the 2-week period following randomization was similar in the two groups, and there was no association between citalopram dose prior to randomization and the reporting of symptoms. Most of the events that did occur were mild in intensity and none resulted in discontinuation from the study. Events occurring at a higher frequency in the placebo group were most associated with the central nervous system (CNS). These events may reflect a re-emergence of depressive symptoms, since only 14.8% of patients randomized to placebo who did not relapse experienced CNS events, a low symptom incidence that was non-significant (P = 0.562) compared to patients continuing treatment (10.9%). Therefore, this assessment suggests that any symptoms associated with rapid discontinuation of citalopram are mild and transient, and emphasizes the significant role re-emerging depression and / or anxiety may play in the assessment and identification of SSRI discontinuation symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After 2 weeks, somnolence was found to be significantly more frequently present in patients who abruptly discontinued the medication (4%) than in those who continued to receive fluoxetine (0%, p < 0.01).”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [17]
In the citing paper
“The clinical data suggested that the syndrome could last up to 3 weeks and could be improved by restarting the same or a similar antidepressant drug (AD).”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [17]
In the citing paper
“At weeks 4 and 6, subjects in the placebo group reported dizziness more frequently than patients in the continuation group (7 vs. 4%, p < 0.05 and 5 vs. 1%, p < 0.05, respectively).”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [17]
In the citing paper
“one of the earliest reviews [17] suggested that a discontinuation syndrome consisting of a cluster of somatic and psychological symptoms could indeed occur.”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [17]
Citations
Cites
Still being checked.
Cited by
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Citalopram use in pregnancy: Prospective comparative evaluation of pregnancy and fetal outcome
Sivojelezova, A., Shuhaiber, S., Sarkissian, L., Einarson, A., & Koren, G. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.05.012 · Cited by 146
Citalopram: a comprehensive review
Pollock, B. G. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.4.681 · Cited by 109
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Metadata
- Authors
- Markowitz, J. S., DeVane, C. L., Liston, H. L., & Montgomery, S. A.
- Affiliations
- Medical University of South Carolina (US)
- Imperial College London (GB)
- Corresponding author
- DeVane, C. L.
- ORCID
- Markowitz, J. S.
- Venue
- International Clinical Psychopharmacology
- Published
- 2000-11
- Volume
- 15
- Issue
- 6
- Pages
- 329-333
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1972856035
- Semantic Scholar
- ae3026d6e806e434b839386bbaed46c70cf64dd7
- Cited by
- 34
- References
- 0
- Citations by year
- 2026: 1 · 2024: 2 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 2 · 2015: 3 · 2012: 2
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- citalopram, selective serotonin reuptake inhibitors, depression relapse prevention, antidepressant discontinuation, adverse drug reactions, central nervous system adverse effects, anxiety
- MeSH terms
- Depressive Disorder, Double-Blind Method, Humans, Psychiatric Status Rating Scales, Recurrence, Substance Withdrawal Syndrome, Citalopram, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. https://app.cochat.ai/papers/10.1097/00004850-200015060-00003
- The paper
- Markowitz, J. S., DeVane, C. L., Liston, H. L., & Montgomery, S. A. (2000). An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200015060-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.